EB-DART-NK01
/ Beijing Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 05, 2026
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
(clinicaltrials.gov)
- P1/2 | N=60 | Recruiting | Sponsor: Beijing Biotech
New P1/2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3 • NCAM1
1 to 1
Of
1
Go to page
1